Tuesday, 17 September 2024
  
Login

Australia's most trusted
source of pharma news

Tuesday, 17 September 2024
Listen to this story 
News

Pharma unveils new era of flexibility

Posted 4 September 2024 AM

Alongside undergoing rapid growth, BeiGene has been diligently working on building a culture that aligns with flexibility, rolling out augmented programs and initiatives to ensure its employees can balance their work with personal life.

Across the Asia Pacific region, the oncology-focused company well-known for BTK inhibitor Brukinsa and PD-1 inhibitor Tevimbra, currently has more than 450 employees, around 250 of which are located in Australia.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (18)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (5)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.